HSBC Initiates Coverage on Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF)

Posted by on Jul 16th, 2023

Analysts at HSBC started coverage on shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF – Get Free Report) in a research report issued to clients and investors on Friday, FlyOnTheWall reports. The brokerage set a “buy” rating on the stock.

Several other brokerages have also weighed in on BIOVF. Morgan Stanley raised Swedish Orphan Biovitrum AB (publ) from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, June 6th. Royal Bank of Canada upgraded Swedish Orphan Biovitrum AB (publ) from a “sector perform” rating to an “outperform” rating in a report on Thursday, April 13th. Finally, Nordea Equity Research upgraded Swedish Orphan Biovitrum AB (publ) from a “hold” rating to a “buy” rating in a report on Friday, April 14th.

Swedish Orphan Biovitrum AB (publ) Stock Performance

Shares of Swedish Orphan Biovitrum AB (publ) stock opened at $19.45 on Friday. Swedish Orphan Biovitrum AB has a fifty-two week low of $18.25 and a fifty-two week high of $26.48. The firm has a market cap of $5.74 billion, a PE ratio of 19.45 and a beta of 0.51. The business’s fifty day moving average is $21.24 and its two-hundred day moving average is $22.48. The company has a quick ratio of 0.45, a current ratio of 0.70 and a debt-to-equity ratio of 0.11.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF – Get Free Report) last issued its quarterly earnings results on Thursday, April 27th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.12. Swedish Orphan Biovitrum AB (publ) had a return on equity of 11.90% and a net margin of 16.38%. The company had revenue of $501.59 million for the quarter, compared to analyst estimates of $475.12 million. Analysts anticipate that Swedish Orphan Biovitrum AB will post 0.9 earnings per share for the current year.

About Swedish Orphan Biovitrum AB (publ)

(Get Free Report)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

Featured Articles

Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.